MedImmune Inc. and American Cyanamid Co. have finalized amarketing and development alliance announced in July. Underthe agreement, MedImmune will receive up to $30 millionfrom Cyanamid (NYSE:ACY) over five years.
The two companies will collaborate in the development of twoMedImmune products for respiratory syncytial virus (RSV), thepolyclonal antibody RespiGam (formerly Respivir) and asecond-generation monoclonal antibody. A product licenseapplication (PLA) for RespiGam is pending at FDA. Thecompanies also will jointly market Cyanamid's anti-infectiveZosyn, which was approved in October. MedImmune, ofGaithersburg, Md., will market the product through its hospitalsales force.
In addition, MedImmune has an option to collaborate on anRSV vaccine being developed by Cyanamid's Lederle PraxisBiologicals division.
MedImmune's stock (NASDAQ:MEDI) was up $2.25 a share onTuesday, closing at $27.25.-- Brenda Sandburg
(c) 1997 American Health Consultants. All rights reserved.